<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="correction"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLOS Glob Public Health</journal-id><journal-id journal-id-type="iso-abbrev">PLOS Glob Public Health</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS Global Public Health</journal-title></journal-title-group><issn pub-type="epub">2767-3375</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40009605</article-id><article-id pub-id-type="pmc">PMC11864505</article-id><article-id pub-id-type="doi">10.1371/journal.pgph.0004337</article-id><article-id pub-id-type="publisher-id">PGPH-D-25-00335</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction: Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes</article-title></title-group><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>2</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>5</volume><issue>2</issue><elocation-id>e0004337</elocation-id><permissions><copyright-statement>&#x000a9; 2025 Geiger et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Geiger et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pgph.0004337.pdf">
</self-uri><related-article related-article-type="corrected-article" ext-link-type="doi" id="related001" xlink:href="10.1371/journal.pgph.0002714">
<article-title>Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes</article-title>
</related-article><counts><fig-count count="0"/><table-count count="4"/><page-count count="3"/></counts></article-meta></front><body><p>
<bold>Keri Geiger, Amita Patil, Chakra Budhathoki, Kelly E. Dooley, Kelly Lowensen, Norbert Ndjeka, Jacqueline Ngozo, Jason E. Farley</bold>
</p><p>In the Abstract section, there is an error in the sixth sentence. The correct sentence is: Those who became detectable or were never suppressed were at significantly increased risk of death (RRR 11.50, 95% CI 1.98-66.65; RRR 9.28, 95% CI 1.53-56.61), treatment failure (RRR 6.37, 95% CI 1.58-25.70; RRR 4.54, 95% CI 1.35-15.24), and loss to follow-up (RRR 7.00, 95% CI 2.83&#x02013;17.31; RRR 2.97, 95% CI 1.02&#x02013;8.61) compared to those who maintained viral suppression.</p><p>Tables 1 to 4 are uploaded incorrectly. Please see the correct <xref rid="pgph.0004337.t001" ref-type="table">Tables 1</xref> to <xref rid="pgph.0004337.t004" ref-type="table">4</xref> here.</p><table-wrap position="float" id="pgph.0004337.t001"><object-id pub-id-type="doi">10.1371/journal.pgph.0004337.t001</object-id><label>Table 1</label><caption><title>Demographic and Clinical Characteristics of PWH (n=1479).</title></caption><alternatives><graphic xlink:href="pgph.0004337.t001" id="pgph.0004337.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="2"/><th align="left" rowspan="2" colspan="1">Total</th><th align="left" colspan="3" rowspan="1">HIV Viral Load Status at MDR-TB Treatment Initiation</th></tr><tr><th align="left" rowspan="1" colspan="1">Virally Suppressed</th><th align="left" rowspan="1" colspan="1">Detectable Viral Load</th><th align="left" rowspan="1" colspan="1">Viral Load Unknown</th></tr><tr><th align="left" colspan="2" rowspan="1">Total</th><th align="left" rowspan="1" colspan="1">1479 (100.0%)</th><th align="left" rowspan="1" colspan="1">457 (30.9%)</th><th align="left" rowspan="1" colspan="1">524 (35.4%)</th><th align="left" rowspan="1" colspan="1">498 (33.7%)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Age, mean (SD, IQR)</td><td align="left" rowspan="1" colspan="1">37.1 (10.3, 30-43)</td><td align="left" rowspan="1" colspan="1">39.1 (10.5, 31-46)</td><td align="left" rowspan="1" colspan="1">36.1 (9.7, 29-42)</td><td align="left" rowspan="1" colspan="1">36.5 (10.5, 29-42)</td></tr><tr><td align="left" rowspan="2" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">809 (54.7%)</td><td align="left" rowspan="1" colspan="1">226 (49.5%)</td><td align="left" rowspan="1" colspan="1">298 (56.9%)</td><td align="left" rowspan="1" colspan="1">285 (57.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">670 (45.3%)</td><td align="left" rowspan="1" colspan="1">231 (50.6%)</td><td align="left" rowspan="1" colspan="1">226 (43.1%)</td><td align="left" rowspan="1" colspan="1">213 (42.8%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Baseline CD4 Count, median (IQR)</td><td align="left" rowspan="1" colspan="1">182 (75-363)</td><td align="left" rowspan="1" colspan="1">385.5 (193-543)</td><td align="left" rowspan="1" colspan="1">164.2 (44.5-273.5)</td><td align="left" rowspan="1" colspan="1">222.1 (66.5-321.5)</td></tr><tr><td align="left" colspan="2" rowspan="1">Baseline BMI, median (IQR)</td><td align="left" rowspan="1" colspan="1">20.7 (17.5-22.8)</td><td align="left" rowspan="1" colspan="1">21.1 (17.6-23.4)</td><td align="left" rowspan="1" colspan="1">20.2 (17.5-21.8)</td><td align="left" rowspan="1" colspan="1">20.8 (17.4-23.2)</td></tr><tr><td align="left" rowspan="4" colspan="1">Prior TB Episodes</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">649 (43.9%)</td><td align="left" rowspan="1" colspan="1">177 (38.7%)</td><td align="left" rowspan="1" colspan="1">213 (40.7%)</td><td align="left" rowspan="1" colspan="1">259 (52.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">One</td><td align="left" rowspan="1" colspan="1">657 (44.4%)</td><td align="left" rowspan="1" colspan="1">225 (49.2%)</td><td align="left" rowspan="1" colspan="1">257 (49.1%)</td><td align="left" rowspan="1" colspan="1">175 (35.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Two or More</td><td align="left" rowspan="1" colspan="1">117 (7.9%)</td><td align="left" rowspan="1" colspan="1">38 (8.3%)</td><td align="left" rowspan="1" colspan="1">43 (8.2%)</td><td align="left" rowspan="1" colspan="1">36 (7.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">56 (3.8%)</td><td align="left" rowspan="1" colspan="1">17 (3.7%)</td><td align="left" rowspan="1" colspan="1">11 (2.1%)</td><td align="left" rowspan="1" colspan="1">28 (5.6%)</td></tr><tr><td align="left" rowspan="2" colspan="1">ART Status at MDR-TB Treatment Initiation</td><td align="left" rowspan="1" colspan="1">Taking ART</td><td align="left" rowspan="1" colspan="1">887 (60.0%)</td><td align="left" rowspan="1" colspan="1">421 (92.1%)</td><td align="left" rowspan="1" colspan="1">266 (50.8%)</td><td align="left" rowspan="1" colspan="1">200 (40.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Not Taking ART</td><td align="left" rowspan="1" colspan="1">592 (40.0%)</td><td align="left" rowspan="1" colspan="1">36 (7.9%)</td><td align="left" rowspan="1" colspan="1">258 (49.2%)</td><td align="left" rowspan="1" colspan="1">298 (59.8%)</td></tr><tr><td align="left" rowspan="4" colspan="1">MDR-TB Regimen</td><td align="left" rowspan="1" colspan="1">Injectable</td><td align="left" rowspan="1" colspan="1">808 (54.6%)</td><td align="left" rowspan="1" colspan="1">248 (54.3%)</td><td align="left" rowspan="1" colspan="1">287 (54.8%)</td><td align="left" rowspan="1" colspan="1">273 (54.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">All-oral</td><td align="left" rowspan="1" colspan="1">386 (26.1%)</td><td align="left" rowspan="1" colspan="1">117 (25.6%)</td><td align="left" rowspan="1" colspan="1">151 (28.8%)</td><td align="left" rowspan="1" colspan="1">118 (23.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Both</td><td align="left" rowspan="1" colspan="1">254 (17.2%)</td><td align="left" rowspan="1" colspan="1">86 (18.9%)</td><td align="left" rowspan="1" colspan="1">76 (14.5%)</td><td align="left" rowspan="1" colspan="1">92 (18.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Individualized</td><td align="left" rowspan="1" colspan="1">31 (2.1%)</td><td align="left" rowspan="1" colspan="1">6 (1.3%)</td><td align="left" rowspan="1" colspan="1">10 (1.9%)</td><td align="left" rowspan="1" colspan="1">15 (3.0%)</td></tr><tr><td align="left" rowspan="4" colspan="1">MDR-TB Outcome</td><td align="left" rowspan="1" colspan="1">Treatment Success</td><td align="left" rowspan="1" colspan="1">925 (62.5%)</td><td align="left" rowspan="1" colspan="1">327 (71.6%)</td><td align="left" rowspan="1" colspan="1">293 (55.9%)</td><td align="left" rowspan="1" colspan="1">305 (61.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Death</td><td align="left" rowspan="1" colspan="1">212 (14.3%)</td><td align="left" rowspan="1" colspan="1">11 (2.4%)</td><td align="left" rowspan="1" colspan="1">19 (3.6%)</td><td align="left" rowspan="1" colspan="1">18 (3.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment Failure</td><td align="left" rowspan="1" colspan="1">48 (3.3%)</td><td align="left" rowspan="1" colspan="1">38 (8.3%)</td><td align="left" rowspan="1" colspan="1">103 (19.7%)</td><td align="left" rowspan="1" colspan="1">71 (14.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lost to Follow-Up</td><td align="left" rowspan="1" colspan="1">294 (19.9%)</td><td align="left" rowspan="1" colspan="1">81 (17.7%)</td><td align="left" rowspan="1" colspan="1">109 (20.8%)</td><td align="left" rowspan="1" colspan="1">104 (20.8%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>PWH, people with HIV; n, number; HIV, human immunodeficiency virus; TB, tuberculosis; MDR-TB, multidrug-resistant TB; SD, standard deviation; IQR, interquartile range; BMI, body mass index; ART, antiretroviral therapy. Note: Some percentages do not add to 100.0% due to rounding.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pgph.0004337.t002"><object-id pub-id-type="doi">10.1371/journal.pgph.0004337.t002</object-id><label>Table 2</label><caption><title>Comparison of Negative Outcomes Among PWH With and Without HIV Viral Suppression at MDR-TB Treatment Initiation Using a Multinomial Model (n=1479).</title></caption><alternatives><graphic xlink:href="pgph.0004337.t002" id="pgph.0004337.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1">Baseline HIV Viral Load (ref. Undetectable)</th><th align="left" colspan="6" rowspan="1">MDR-TB Treatment Outcome</th></tr><tr><th align="left" colspan="2" rowspan="1">Died</th><th align="left" colspan="2" rowspan="1">Treatment Failure</th><th align="left" colspan="2" rowspan="1">Lost to Follow-Up</th></tr><tr><th align="left" rowspan="1" colspan="1">RRR&#x002c6;</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">RRR&#x002c6;</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">RRR</th><th align="left" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Detectable</td><td align="left" rowspan="1" colspan="1">2.12<sup>*</sup></td><td align="left" rowspan="1" colspan="1">1.11-4.07</td><td align="left" rowspan="1" colspan="1">1.72</td><td align="left" rowspan="1" colspan="1">0.96-3.05</td><td align="left" rowspan="1" colspan="1">1.39</td><td align="left" rowspan="1" colspan="1">0.92-2.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">1.64</td><td align="left" rowspan="1" colspan="1">0.85-3.16</td><td align="left" rowspan="1" colspan="1">1.64</td><td align="left" rowspan="1" colspan="1">0.91-2.94</td><td align="left" rowspan="1" colspan="1">1.28</td><td align="left" rowspan="1" colspan="1">0.80-2.04</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>MDR-TB, multidrug-resistant tuberculosis; HIV, human immunodeficiency virus; ref., reference; RRR, relative risk ratio; CI, confidence interval; *, p&#x0003c;0.05; **, p&#x0003c;0.01; ***, p&#x0003c;0.001. <bold><underline>&#x002c6;</underline></bold><underline>Note</underline>: adjusted for age, sex, baseline CD4 count, and baseline BMI.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pgph.0004337.t003"><object-id pub-id-type="doi">10.1371/journal.pgph.0004337.t003</object-id><label>Table 3</label><caption><title>MDR-TB Treatment Outcome by HIV Viral Load Status Over Time (n=673).</title></caption><alternatives><graphic xlink:href="pgph.0004337.t003" id="pgph.0004337.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">HIV Viral Load Status Over Time</th><th align="left" rowspan="2" colspan="1">Total</th><th align="left" colspan="4" rowspan="1">MDR-TB Treatment Outcome, n (%)</th></tr><tr><th align="left" rowspan="1" colspan="1">Success</th><th align="left" rowspan="1" colspan="1">Died</th><th align="left" rowspan="1" colspan="1">Failure</th><th align="left" rowspan="1" colspan="1">Lost to Follow-Up</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">673 (100.0%)</td><td align="left" rowspan="1" colspan="1">537 (79.8%)</td><td align="left" rowspan="1" colspan="1">46 (6.8%)</td><td align="left" rowspan="1" colspan="1">23 (3.4%)</td><td align="left" rowspan="1" colspan="1">67 (10.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Maintained Suppression</td><td align="left" rowspan="1" colspan="1">194 (100.0%)</td><td align="left" rowspan="1" colspan="1">176 (90.7%)</td><td align="left" rowspan="1" colspan="1">4 (2.1%)</td><td align="left" rowspan="1" colspan="1">4 (2.1%)</td><td align="left" rowspan="1" colspan="1">10 (5.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Became Suppressed</td><td align="left" rowspan="1" colspan="1">267 (100.0%)</td><td align="left" rowspan="1" colspan="1">223 (83.5%)</td><td align="left" rowspan="1" colspan="1">15 (5.6%)</td><td align="left" rowspan="1" colspan="1">8 (3.0%)</td><td align="left" rowspan="1" colspan="1">21 (7.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Became Detectable</td><td align="left" rowspan="1" colspan="1">94 (100.0%)</td><td align="left" rowspan="1" colspan="1">53 (56.4%)</td><td align="left" rowspan="1" colspan="1">13 (13.8%)</td><td align="left" rowspan="1" colspan="1">5 (5.3%)</td><td align="left" rowspan="1" colspan="1">23 (24.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Never Suppressed</td><td align="left" rowspan="1" colspan="1">118 (100.0%)</td><td align="left" rowspan="1" colspan="1">85 (72.0%)</td><td align="left" rowspan="1" colspan="1">14 (11.9%)</td><td align="left" rowspan="1" colspan="1">6 (5.1%)</td><td align="left" rowspan="1" colspan="1">13 (11.0%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>MDR-TB, multidrug-resistant tuberculosis; HIV, human immunodeficiency virus; n, number. Note: Some percentages do not add to 100.0% due to rounding.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pgph.0004337.t004"><object-id pub-id-type="doi">10.1371/journal.pgph.0004337.t004</object-id><label>Table 4</label><caption><title>Comparison of Negative Outcomes Among PWH According to HIV Viral Load Changes Between MDR-TB Treatment Initiation and MDR-TB Treatment Outcome Using a Multinomial Model (n=673).</title></caption><alternatives><graphic xlink:href="pgph.0004337.t004" id="pgph.0004337.t004g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1">HIV Viral Load Status Over Time (ref. Maintained Suppression)</th><th align="left" colspan="6" rowspan="1">MDR-TB Treatment Outcome</th></tr><tr><th align="left" colspan="2" rowspan="1">Died</th><th align="left" colspan="2" rowspan="1">Treatment Failure</th><th align="left" colspan="2" rowspan="1">Lost to Follow-Up</th></tr><tr><th align="left" rowspan="1" colspan="1">RRR&#x002c6;</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">RRR&#x002c6;</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">RRR&#x002c6;</th><th align="left" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Became Suppressed</td><td align="left" rowspan="1" colspan="1">2.75</td><td align="left" rowspan="1" colspan="1">0.66-11.42</td><td align="left" rowspan="1" colspan="1">1.53</td><td align="left" rowspan="1" colspan="1">0.83-2.84</td><td align="left" rowspan="1" colspan="1">1.22</td><td align="left" rowspan="1" colspan="1">0.40-3.76</td></tr><tr><td align="left" rowspan="1" colspan="1">Became Detectable</td><td align="left" rowspan="1" colspan="1">11.50**</td><td align="left" rowspan="1" colspan="1">1.98-66.65</td><td align="left" rowspan="1" colspan="1">6.37**</td><td align="left" rowspan="1" colspan="1">1.58-25.70</td><td align="left" rowspan="1" colspan="1">7.00***</td><td align="left" rowspan="1" colspan="1">2.83-17.31</td></tr><tr><td align="left" rowspan="1" colspan="1">Never Suppressed</td><td align="left" rowspan="1" colspan="1">9.28*</td><td align="left" rowspan="1" colspan="1">1.52-56.61</td><td align="left" rowspan="1" colspan="1">4.54*</td><td align="left" rowspan="1" colspan="1">1.35-15.24</td><td align="left" rowspan="1" colspan="1">2.97*</td><td align="left" rowspan="1" colspan="1">1.02-8.61</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>MDR-TB, multidrug-resistant tuberculosis; HIV, human immunodeficiency virus; ref., reference category; RRR, relative risk ratio; CI, conficence interval; *, p&#x0003c;0.05; **, p&#x0003c;0.01; ***, p&#x0003c;0.001. <bold><underline>&#x002c6;</underline></bold><underline>Note</underline>: adjusted for age, sex, length of MDR-TB treatment, MDR-TB regimen, and arm of parent study.</p></fn></table-wrap-foot></table-wrap></body><back><ref-list><title>Reference</title><ref id="pgph.0004337.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Geiger</surname><given-names>K</given-names></name>, <name><surname>Patil</surname><given-names>A</given-names></name>, <name><surname>Budhathoki</surname><given-names>C</given-names></name>, <name><surname>Dooley</surname><given-names>KE</given-names></name>, <name><surname>Lowensen</surname><given-names>K</given-names></name>, <name><surname>Ndjeka</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes</article-title>. <source>PLOS Glob Public Health</source>. <year>2024</year>;<volume>4</volume>(<issue>5</issue>):<fpage>e0002714</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pgph.0002714</pub-id>
<pub-id pub-id-type="pmid">38709764</pub-id>
</mixed-citation></ref></ref-list></back></article>